别嘌呤醇所致的严重皮肤不良反应与HLA~* B-5801等位基因相关性的研究进展

Research Progress of the Correlation Between Allopurinol-Induced Severe Cutaneous Adverse Drug Reactions and HLA-B~* 5801 Allele

目的:综述别嘌呤醇所致的严重皮肤不良反应与HLA~*B-5801等位基因相关性的最新研究进展。方法:检索并整理国内外与本研究目的相关的文献,从别嘌呤醇所致的严重皮肤不良反应和HLA~*B-5801等位基因的相关性在不同地区人群中的研究情况及其发生机制两方面,综述最新研究进展。结果:别嘌呤醇所致的严重皮肤不良反应和HLA~*B-5801等位基因的相关性,在亚洲人群中存在显著相关性,而在欧美人群中这种相关性并不明显。结论:初次使用别嘌呤醇的患者(特别是中国汉族人群)用药前最好进行HLA-B~*5801等位基因检测,对于该等位基因阳性患者,不建议使用别嘌呤醇而应采取别嘌呤醇诱导耐受方案或者药物替代治疗。

Objective:To review the recent research progress of the correlation between Allopurinol-Induced Severe Cutaneous Adverse Drug Reactions and HLA-B*5801 allele.Methods:Search and sort out the literature related to the purpose of this study at home and abroad,from the two aspects of correlation between Allopurinol-Induced Severe Cutaneous Adverse Drug Reactions and HLA-B*5801 allele in the population in different regions and generating mechanism,review the latest research progress.Results:The relevance of HLA-B*5801 allele associated with Severe Cutaneous Adverse Drug Reactions caused by Allopurinol is stronger in Asia population,but weaker in Europe and the United States.Conclusion:It is recommended that the first use of allopurinol in patient(particularly in Han Chinese)should detect HLA-B*5801 allele before medication,for the allele-positive patient,allopurinol don't be recommend for use and take allopurinol-induced tolerance regimen or drug replacement therapy.